Results 11 to 20 of about 104,267 (299)

Beta-blocker use and up-titration after acute ST-segment elevation myocardial infarction: a cohort study

Swiss Medical Weekly, 2020
BACKGROUND The European Society of Cardiology recommends beta-blocker prescription after ST-segment elevation myocardial infarction (STEMI).
Christel Bruggmann, Stéphane Fournier, Alice Panchaud, Olivier Muller, Farshid Sadeghipour, Pierre Voirol   +5 more
doaj   +2 more sources

Factors associated with β-blocker initiation and discontinuation in a population-based cohort of seniors newly diagnosed with heart failure

Patient Preference and Adherence, 2016
Catherine Girouard,1–3 Jean-Pierre Grégoire,1–3 Paul Poirier,2,4 Jocelyne Moisan1–3 1Chair on Adherence to Treatments, Université Laval, 2Faculty of Pharmacy, Université Laval, 3Population Health and Optimal Health
Girouard C, Grégoire JP, Poirier P, Moisan J   +3 more
doaj   +1 more source

Beta-blockers: friend or foe in asthma?

International Journal of General Medicine, 2013
Bente Arboe, Charlotte Suppli UlrikDepartment of Pulmonary Medicine, Hvidovre Hospital and University of Copenhagen, Hvidovre, DenmarkBackground and aim: Recently, β-blockers have been suggested as a potential maintenance treatment option for asthma.
Arboe B, Ulrik CS
doaj   +2 more sources

Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease

International Journal of COPD, 2017
Naohiro Oda,1 Nobuaki Miyahara,1,2 Hirohisa Ichikawa,3 Yasushi Tanimoto,4 Kazuhiro Kajimoto,5 Makoto Sakugawa,6 Haruyuki Kawai,7 Akihiko Taniguchi,1 Daisuke Morichika,1 Mitsune Tanimoto,1 Arihiko Kanehiro,1 Katsuyuki Kiura1 1Department of Allergy and ...
Oda N, Miyahara N, Ichikawa H, Tanimoto Y, Kajimoto K, Sakugawa M, Kawai H, Taniguchi A, Morichika D, Tanimoto M, Kanehiro A, Kiura K   +11 more
doaj   +1 more source

Impact of beta‐blocker use on the long‐term outcomes of heart failure patients with chronic obstructive pulmonary disease

ESC Heart Failure, 2021
Aims The number of patients with both chronic obstructive pulmonary disease (COPD) and heart failure (HF) is increasing in Asia, and these conditions often coexist.
Yoshiaki Kubota, Wan Ting Tay, Tiew‐Hwa Katherine Teng, Kuniya Asai, Takashi Noda, Kengo Kusano, Atsushi Suzuki, Nobuhisa Hagiwara, Shinji Hisatake, Takanori Ikeda, Ryobun Yasuoka, Takashi Kurita, Wataru Shimizu, ASIAN‐HF Executive Committee   +13 more
doaj   +1 more source

Beta‐blocker use and mortality among patients with systolic heart failure and pacemaker rhythm

ESC Heart Failure, 2023
Aims Beta‐blockers are proven to improve survival among patients with heart failure with reduced ejection fraction. Their efficacy in patients with heart failure with reduced ejection fraction and pacemaker devices has not been demonstrated.
Andrew S. Perry, Aldo P. Maggioni, Luigi Tavazzi, Wayne C. Levy   +3 more
doaj   +1 more source

Evaluation of beta-blocker effects on patients with traumatic brain injury: interventional double-blinded randomized controlled trial

Ain Shams Journal of Anesthesiology, 2023
Background Traumatic brain injury (TBI) is a major cause of death and disability throughout the world. Traumatic injury is one of the most common causes of death in people under the age of 40 worldwide, and one-third of all trauma-related deaths are a ...
Mostafa Saieed Mansour, Nihal Shahat El Seidy, Yasser Ibrahim Fathey   +2 more
doaj   +1 more source

Influence of beta-blocker therapy on the risk of infections and death in patients at high risk for stroke induced immunodepression. [PDF]

PLoS ONE, 2018
Stroke-induced immunodepression is a well characterized complication of acute ischemic stroke. In experimental studies beta-blocker therapy reversed stroke-induced immunodepression, reduced infection rates and mortality.
Ilko L Maier, Johannes C Becker, Johanna Rosemarie Leyhe, Marlena Schnieder, Daniel Behme, Marios-Nikos Psychogios, Jan Liman   +6 more
doaj   +1 more source

The β-blocker Nebivolol Is a GRK/β-arrestin Biased Agonist [PDF]

, 2013
Nebivolol, a third generation β-adrenoceptor (β-AR) antagonist (β-blocker), causes vasodilation by inducing nitric oxide (NO) production. The mechanism via which nebivolol induces NO production remains unknown, resulting in the genesis of much of the ...
Jackson, Edwin K., Blessing, CP, Tammy Liu, Liu, Tammy, Liu, T, Christopher P Blessing, Jackson Edwin K., Liu Tammy, Gul, R, Pulakat, Lakshmi, Pulakat, L, Murat Bastepe, Blessing, Christopher P., Edwin K Jackson, Catherine E Erickson, Rukhsana Gul, Bastepe Murat, Lakshmi Pulakat, Andresen Bradley T., Nguyen, J, Pulakat Lakshmi, Gul, Rukhsana, Andresen, Bradley T., Erickson, CE, Blessing Christopher P., Holowka, David, Nguyen Jenny, Bastepe, Murat, Jackson, EK, Andresen, BT, Gul Rukhsana, Jenny Nguyen, Erickson Catherine E., Bastepe, M, Erickson, Catherine E., Nguyen, Jenny, Bradley T Andresen   +36 more
core   +1 more source

Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients

Cardiovascular Diabetology, 2019
Background Although beta blockers could increase the risk of hypoglycemia, the difference between subtypes on hypoglycemia and mortality have not been studied.
Kathleen Dungan, Jennifer Merrill, Clarine Long, Philip Binkley   +3 more
doaj   +1 more source